Fri, 02-Jun-2023
Monday 10 Aug 2020 , 6:27 am

Viva Biotech and Langhua Pharmaceutical Reached the Strategic Acquisition Agreement

The acquisition will enable The Company to acquire an established Contract Development & Manufacturing Organization (CDMO) platform with solid track record and reputation, and expand the diversity and geographical coverage of customer groups.
By SIN Bureau
Share at:

Viva Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Viva Biotech" or "The Company") entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 80% of the equity interest in Zhejiang Langhua Pharmaceutical Co., Ltd (hereinafter referred to as "Langhua Pharmaceutical"), at the Consideration of RMB 2,560 million. The synergy between Viva Biotech and Langhua Pharmaceutical, in areas of R&D, design and manufacturing of global pharmaceutical market is brought about by the acquisition. It is of great strategic significance for The Company to conduct vertical integration and expansion into CDMO (Contract R&D and Production Organization) business, and establish a comprehensive one-stop drug services platform.

The acquisition will enable The Company to acquire an established Contract Development & Manufacturing Organization (CDMO) platform with solid track record and reputation, and expand the diversity and geographical coverage of customer groups. Through more comprehensive end-to-end services, CDMO business will help The Company to extend the existing and potential customer groups, effectively enhancing the income stream, enabling the future high-speed growth service demand of portfolio companies under EFS model, and expanding the portfolio of potential incubation projects. Based on the existing core advantages, Viva Biotech will further strengthen and expand the drug research, design and manufacturing capacity by investing more high-quality talents and facilities, including but not limited to expanding its CMC capacity and integrating its operation with the existing business of The Company. Through providing more abundant and high-quality services, The Company aims to improve the market competitiveness, so as to gain a position which allows prospective clients, including both startup biotech companies and multi-national pharmaceutical companies, to select The Company as their priority partner for comprehensive outsourcing services.

Dr. Mao Chen Cheney, the Chairman and CEO of Viva Biotech said, "The strategic acquisition agreement we made with Langhua Pharmaceutical will effectively improve the integrated service capability in new drug R&D and overall competitiveness for both sides. We have steady confidence towards the business prospects and potential future growth of Langhua Pharmaceutical. In the future, Viva Biotech will continue to take advantage of our existing technology platforms, world-class drug discovery talents and client synergy, to continue to expand further downstream towards later stage drug development through strategic cooperation, investment, and M&A. Our partners and clients can benefit from improved operational efficiency and platform capacity. We will accelerate the vertical integration of innovative drug service chain, and help our customers and portfolio companies to better develop and commercialize their products."

Mr. Mengchun Shan, Chairman of Langhua Pharmaceutical said, "The strategic acquisition agreement that reached with Viva Biotech marks an important moment in the development of Langhua Pharmaceutical. Our rich accumulation in the field of CDMO will show a good synergistic effect with the leading technological of Viva Biotech in the field of innovative drug discovery. In the future, we will continue to provide clients with more comprehensive drug development services. Driven by the innovation and cultivated by differentiated competitive advantages, Langhua Pharmaceutical aims to become the most valuable and innovating API supplier and the clients' preferred CDMO partner."

The EGM will be convened for the Shareholders to consider and, if though fit, to approve among other matters, the acquisition. After completion of the acquisition, Langhua Pharmaceutical will serve as the enlarged group's sole CDMO platform for small molecule drugs and advanced intermediate, being responsible for the operation related to the development, optimization and commercialization of small molecule drugs and intermediate.

Neha Mule

Neha writes articles on sectors including medicine, food, materials, and science & technology. A qualified statistician, she has the ability to observe and analyze the trends in global markets and write compelling articles that help CXOs in decision making. She is a bookworm and loves to read fiction, lifestyle, science and technology. Neha comes with 6 years of experience in content writing and editing that involves blog writing, preparation of study materials and OERs.

More from Neha Mule

Related News